On this page
PDX1
pancreatic and duodenal homeobox 1
PDX1 is located on the long (q) arm of chromosome 13, at band 13q12.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 13 in the library →Available at Jeen Health
Clinical tests that include this
Overview
PDX1 (pancreatic and duodenal homeobox 1) is located on chromosome 13 and encodes a homeodomain-containing transcription factor critical for pancreatic organogenesis. During embryonic development, PDX1 orchestrates the genetic programmes that specify pancreatic tissue from the foregut endoderm, ensuring proper formation of both exocrine and endocrine compartments. In mature beta cells, the protein continues to regulate insulin gene transcription and maintain glucose-responsive insulin secretion. Pathogenic variants in PDX1 are recognised causes of monogenic diabetes, a group of inherited conditions distinct from the more common type 1 and type 2 diabetes. The clinical phenotype associated with PDX1 dysfunction ranges from complete pancreatic agenesis in individuals with two affected gene copies to maturity-onset diabetes of the young (MODY) in those with a single pathogenic variant.
What the gene does
The PDX1 protein functions as a sequence-specific DNA-binding transcription factor that recognises and binds to regulatory elements within the promoters of target genes involved in pancreatic development and glucose metabolism. During embryogenesis, PDX1 is expressed in pancreatic progenitor cells where it activates developmental programmes essential for differentiation of both insulin-secreting beta cells and digestive-enzyme-producing acinar cells. In adult beta cells, PDX1 directly regulates transcription of the insulin gene and other genes involved in glucose sensing and insulin secretion, thereby linking nutrient availability to appropriate hormonal output. The protein's activity is modulated by post-translational modifications and interactions with co-factors that fine-tune its transcriptional output in response to metabolic signals. Loss of PDX1 function impairs beta-cell maturation, reduces insulin production, and compromises the cellular machinery required for glucose-stimulated insulin release, ultimately resulting in hyperglycaemia.
Video: Genetics 101
Chromosome location
PDX1 is located on the long arm of chromosome 13 at band 13q12.2. The gene spans genomic DNA and contains two exons that together encode a 283-amino-acid protein. This chromosomal region is conserved across mammalian species, reflecting the fundamental importance of PDX1 in vertebrate pancreatic biology.
Protein structure
The PDX1 protein comprises 283 amino acids organised into several functional regions. The N-terminal region includes a transactivation domain spanning amino acids 13 to 73, which recruits transcriptional machinery to gene promoters; within this region, a disordered segment (amino acids 34-71) provides structural flexibility important for protein-protein interactions. A short Antp-type hexapeptide motif at positions 118-123 contributes to DNA-binding specificity. The central homeobox domain (amino acids 146-205) forms a characteristic helix-turn-helix structure that directly contacts DNA, recognising specific nucleotide sequences in target gene regulatory regions. Overlapping with the C-terminal portion of the homeobox is a nuclear localisation signal (amino acids 197-203) that directs the protein into the nucleus where it accesses chromatin. The C-terminal region (amino acids 201-283) is disordered, likely facilitating interactions with co-regulatory proteins that modulate PDX1 transcriptional activity.
Key variants
Pathogenic variants in PDX1 exhibit variable penetrance and expressivity depending on whether one or both gene copies are affected. Biallelic loss-of-function variants typically result in severe pancreatic agenesis presenting at birth, whereas heterozygous variants are associated with maturity-onset diabetes of the young, characterised by onset in adolescence or early adulthood. The variant spectrum includes missense changes affecting the homeobox domain that disrupt DNA binding, frameshift and nonsense variants leading to premature termination, and deletions removing critical functional regions.
Sample of pathogenic variants
4 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.532G>A | p.Glu178Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Pancreatic agenesis 1 |
c.494_497delinsAC | p.Phe165fs | Pathogenic | ★☆☆☆ | Familial Monogenic Diabetes (Maturity Onset Diabetes Of The Young 4)/Neonatal Diabetes Mellitus |
c.533A>G | p.Glu178Gly | Pathogenic | ★☆☆☆ | Maturity-onset diabetes of the young type 4 |
c.492G>T | p.Glu164Asp | Pathogenic; risk factor | - | Diabetes mellitus type 2, susceptibility to |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in PDX1 cause monogenic diabetes, a genetically heterogeneous group of inherited diabetes disorders. Individuals with biallelic pathogenic variants may present with neonatal diabetes and pancreatic insufficiency due to complete or near-complete absence of pancreatic tissue. Heterozygous carriers typically develop a milder phenotype classified as MODY type 4, with progressive beta-cell dysfunction leading to diabetes diagnosis in late childhood, adolescence, or young adulthood. Unlike common forms of diabetes, PDX1-related diabetes follows clear inheritance patterns and may be managed differently depending on the underlying molecular defect.
No disease links recorded for this gene in our reference set.
UK clinical status
Within the NHS Genomic Medicine Service, PDX1 is included on several PanelApp panels relevant to inherited diabetes. The gene holds green (high evidence) status on the Diabetes with additional phenotypes suggestive of a monogenic aetiology panel, the Familial diabetes panel, the Monogenic diabetes panel (R141), and the Neonatal diabetes panel (R143). This classification reflects strong evidence supporting PDX1 testing in individuals with clinical features suggesting monogenic diabetes, particularly when diabetes presents early in life or occurs alongside pancreatic exocrine dysfunction.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the difference between PDX1-related diabetes and common type 2 diabetes?
PDX1-related diabetes is a rare, inherited condition caused by specific genetic variants passed from parent to child, typically presenting earlier in life with distinct clinical features. Common type 2 diabetes is a multifactorial condition influenced by many genes and environmental factors, usually developing in middle age or later.
How is PDX1 inherited?
PDX1 follows an autosomal dominant inheritance pattern for maturity-onset diabetes of the young (one altered copy from either parent is sufficient to cause disease), whilst severe pancreatic agenesis requires two altered copies (autosomal recessive). Each child of a parent carrying a pathogenic variant has a 50% chance of inheriting that variant.
Can genetic testing for PDX1 help guide diabetes treatment?
Identifying a PDX1 variant can inform treatment decisions, as some individuals with monogenic diabetes respond differently to medications compared to those with common type 1 or type 2 diabetes. A genetic diagnosis may allow for more tailored management, though treatment decisions should always be made in consultation with a healthcare professional.